Leerink Swann Upgrades Allergan To Outperform
Analysts at Leerink Swann upgraded Allergan (NYSE: AGN) from Market Perform to Outperform.
The target price for Allergan is set to $184.
Allergan shares have surged 64.59% over the past 52 weeks, while the S&P 500 index has gained 12.49% in the same period.
Allergan's shares dropped 3.30% to close at $151.92 yesterday.
Latest Ratings for AGN
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Apr 2020 | SunTrust Robinson Humphrey | Downgrades | Buy | Hold |
| Mar 2020 | CFRA | Downgrades | Buy | Hold |
| Feb 2020 | SunTrust Robinson Humphrey | Maintains | Buy |
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted-In: Leerink SwannUpgrades Analyst Ratings
